Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03983395 · ClinicalTrials.gov registry record · Phase 1
Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer
A Phase 1 study, sponsored by Ichnos Sciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03983395 is a Phase 1 study that was terminated before completion, run by Ichnos Sciences. The registered enrollment target is 1 participants.
The verdict
NCT03983395, a Phase 1 study, was terminated before completion, sponsored by Ichnos Sciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.
Interventions
- BIOLOGICAL ISB 1302 250 ng/kg
- BIOLOGICAL ISB 1302 325 ng/kg
- BIOLOGICAL ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22
- BIOLOGICAL ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22
- BIOLOGICAL ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-04-08 |
| Est. Completion | 2020-07-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03983395
The ClinicalTrials.gov registry entry for NCT03983395 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ichnos Sciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which ISB 1302 250 ng/kg is the first listed.
NCT03983395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03983395 about?
NCT03983395 is a clinical study titled "Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer". The purpose of this study is to determine the safety profile, maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single agent ISB1302 in subjects with HER2-positive metastatic breast cancer who have been treated with all known therapies known to confer clinical benefit.
What is the current status of trial NCT03983395?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2020-04-08. Estimated completion is 2020-07-24.
What interventions are being tested in trial NCT03983395?
The interventions under investigation include: ISB 1302 250 ng/kg (BIOLOGICAL), ISB 1302 325 ng/kg (BIOLOGICAL), ISB 1302 325 ng/kg-D1;425 ng/kg -D8,D15,D22 (BIOLOGICAL), ISB 1302 325 ng/kg-D1;550 ng/kg -D8,D15,D22 (BIOLOGICAL), ISB 1302 325ng/kgD1;550 ng/kg D8;700 ng/kgD15,22 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03983395?
This trial is sponsored by Ichnos Sciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.